In 2025, J. Molner continued to expand its operations in the U.S. generic pharmaceuticals market. During the reporting period, the Company launched two new prescription dermatology products in the United States, bringing the total number of marketed products in the U.S. to four by year-end. The Company also continued its generic drug development projects and entered into new collaboration agreements with U.S.-based pharmaceutical companies.
The Group's revenue for 2025 amounted to EUR 1.15 million (2024: EUR 2.29 million). The decrease in revenue was primarily attributable to the different structure of development agreements, under which a portion of receipts was recognized as advance payments rather than revenue.
The Group's EBITDA amounted to EUR 0.56 million, compared to negative EBITDA of EUR 1.83 million in 2024. The Group reported a net profit of EUR 0.13 million for the financial year, compared to a net loss of EUR 2.44 million in the previous year. The net profit was significantly influenced by the restructuring of the Company's capital structure, during which a portion of creditors' claims was waived and a portion was converted into equity.
During 2025, the Company implemented measures to strengthen its capital structure, including an increase in share capital and agreements with creditors aimed at improving the Company's financial position.
As of 31 December 2025, the Group's equity amounted to EUR 2.11 million (31 December 2024: EUR 0.92 million).
Following the reporting date, J. Molner AS completed the previously announced acquisition of a portfolio of pharmaceutical product registrations in the United States. The transaction significantly expands the Company's product portfolio and strengthens its market position in the U.S. market.
The audited Annual Report for 2025 is attached to this announcement.
For additional information please contact:
Sten Akel
J. Molner AS
CFO
+372 550 5259
s.akel@jmolner.com